Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Astegolimab - Genentech

Next Previous
Drug Profile

Astegolimab - Genentech

Alternative Names: AMG-282; Anti-ST2; MSTT 1041 A; RG 6149; RO 7187807; ST2 MAb

Latest Information Update: 24 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech; Roche
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Allergic asthma; Atopic dermatitis
  • Discontinued Asthma; COVID-19 pneumonia; Rhinosinusitis

Most Recent Events

  • 21 Jul 2025 Efficacy and adverse events data from a phase IIb ALIENTO trial in Chronic obstructive pulmonary disease released by Genetech
  • 21 Jul 2025 Efficacy and adverse events data from a phase III ARNASA trial in Chronic obstructive pulmonary disease released by Genetech
  • 07 Jul 2025 Genentech completes the phase IIb ALIENTO clinical trials in Chronic obstructive pulmonary disease (Combination therapy) in US, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Czech Republic, Denmark, France, Germany, Hong Kong, Israel, Mexico, Netherlands, New Zealand, Peru, Poland, Romania, South Africa, South Korea, Spain, Sweden, and the UK (SC) (NCT05037929)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top